Financial News

Financial Report: Lilly

Newer products boost growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly   3Q Revenues: $5.2 billion (+5%) 3Q Earnings:  $778.0 million (-3%) YTD Revenues: $15.5 billion (+6%) YTD Earnings: $2.0 billion (+2%) Comments: Newer pharmaceutical products boosted sales in the quarter. Trulicity sales were $243.6 million in the quarter. Cyramza sales were up 43% to $159.0 million. Taltz sales were $32.5 million and Jardiance sales were $47.5 million in the quarter. Humalog sales were down 9% to $640.8 million driven by lower realized prices, partially off...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters